Ruxolitinib - Isotope Labelled Standards
References
FAQ's
References
- Rodgers, James D.; Shepard, Stacey; Maduskuie, Thomas P.; Wang, Haisheng; Falahatpisheh, Nikoo; Rafalski, Maria; Arvanitis, Argyrios G.; Storace, Louis; Jalluri, Ravi Kumar; Fridman, Jordan S.; et al., “Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors”, Incyte Corp., United States, US8415362B2, April 9. 2013
- Harsh Thakkar, Kalyani Sharma, Nancy Goyal, and Ravi P. Shah, “LC-HRMS studies on ruxolitinib degradation: a comprehensive approach during drug development”, Analytical methods, Issue4, 2022,
Frequently Asked Questions
What are the factors that influence the synthesis of Ruxolitinib impurities?
The factors influencing the synthesis of Ruxolitinib impurities include the choice of starting materials, reaction conditions, solvent choice, temperature, and catalysts.
What are the degradation impurities in Ruxolitinib?
The degradation impurities in Ruxolitinib may include impurities formed due to chemical or physical degradation of the drug, such as hydrolysis, oxidation, and photodegradation.
How do analytical techniques help identify and quantify?
Analytical techniques such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), etc., help identify and quantify Ruxolitinib impurities.
How are Ruxolitinib impurities isolated and purified?
Ruxolitinib impurities are isolated and purified using techniques, column chromatography, recrystallization, and preparative HPLC.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.